AP NEWS

Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco

December 19, 2018

VICTORIA, British Columbia--(BUSINESS WIRE)--Dec 19, 2018--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00am PST, 1pm EST.

The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of will also be archived on the site following the event.

About Aurinia

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.

We seek safe harbor.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005177/en/

CONTACT: Investors:

Celia Economides

VP, Corporate & Public Affairs

IR@auriniapharma.comMedia:

Christopher Hippolyte, , 212-364-0458

Christopher.hippolyte@inventivhealth.com

KEYWORD: UNITED STATES NORTH AMERICA CANADA CALIFORNIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH OTHER SCIENCE SCIENCE

SOURCE: Aurinia Pharmaceuticals Inc.

Copyright Business Wire 2018.

PUB: 12/19/2018 08:00 AM/DISC: 12/19/2018 08:01 AM

http://www.businesswire.com/news/home/20181219005177/en

AP RADIO
Update hourly